This episode delves into the crucial question of seizure prophylaxis in patients undergoing glioma surgery, drawing insights from the SPRING Randomized Controlled Trial. The study abstract, published in Health Technology Assessment in 2026, examines the frequent perioperative use of levetiracetam despite current guidelines not recommending routine prophylactic antiseizure medication for seizure-naive glioma patients. We will explore the trial's findings and discuss the significant clinical implications for neurosurgical practice and patient management concerning seizure risk and treatment. This content is for informational purposes and does not constitute medical advice.